Regulated conformation changes in C-reactive protein orchestrate its role in atherogenesis

Chinese Science Bulletin

Volumn 58, Issue 14, 2013, Pages 1642-1649

  Ma, Xiao ^a   Ji, Shang Rong ^b   Wu, Yi ^b  

^a LANZHOU UNIVERSITY OF TECHNOLOGY   (China)

^b LANZHOU UNIVERSITY   (China)

Author keywords

atherosclerosis; C reactive protein; inflammation; redox

Indexed keywords

EID: 84877610165     PISSN: 10016538     EISSN: 18619541     Source Type: Journal    
DOI: 10.1007/s11434-012-5591-3     Document Type: Review

References (106)

1. Pepys M B, Hirschfield G M. C-reactive protein: A critical update. J Clin Invest, 2003, 111: 1805-1812.
2. Volanakis J E. Human C-reactive protein: Expression, structure, and function. Mol Immunol, 2001, 38: 189-197.
3. Bottazzi B, Doni A, Garlanda C, et al. An integrated view of humoral innate immunity: Pentraxins as a paradigm. Annu Rev Immunol, 2010, 28: 157-183.
4. Marnell L L, Mold C, Volzer M A, et al. C-reactive protein binds to Fc gamma RI in transfected COS cells. J Immunol, 1995, 155: 2185-2193.
5. Bharadwaj D, Stein M P, Volzer M, et al. The major receptor for C-reactive protein on leukocytes is fcgamma receptor II. J Exp Med, 1999, 190: 585-590.
6. Lu J, Marjon K D, Marnell L L, et al. Recognition and functional activation of the human IgA receptor (FcalphaRI) by C-reactive protein. Proc Natl Acad Sci USA, 2011, 108: 4974-4979.
7. Fujita Y, Kakino A, Harada-Shiba M, et al. C-reactive protein uptake by macrophage cell line via class-A scavenger receptor. Clin Chem, 2010, 56: 478-481.
8. Fujita Y, Kakino A, Nishimichi N, et al. Oxidized LDL receptor LOX-1 binds to C-reactive protein and mediates its vascular effects. Clin Chem, 2009, 55: 285-294.
9. Casas J P, Shah T, Hingorani A D, et al. C-reactive protein and coronary heart disease: A critical review. J Intern Med, 2008, 264: 295-314.
10. Reifenberg K, Lehr H A, Baskal D, et al. Role of C-reactive protein in atherogenesis: Can the apolipoprotein E knockout mouse provide the answer? Arterioscler Thromb Vasc Biol, 2005, 25: 1641-1646.
11. Ridker P M, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med, 2002, 347: 1557-1565.
12. Danesh J, Wheeler J G, Hirschfield G M, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med, 2004, 350: 1387-1397.
13. Zacho J, Tybjaerg-Hansen A, Jensen J S, et al. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med, 2008, 359: 1897-1908.
14. Ridker P M, Danielson E, Fonseca F A, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med, 2008, 359: 2195-2207.
15. Nissen S E, Tuzcu E M, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med, 2005, 352: 29-38.
16. Torzewski J, Li K, Zimmermann O. Road map to drug discovery and development-inhibiting C-reactive protein for the treatment of cardiovascular disease. J Bioequiv Availab, 2011, S1: 1-5.
17. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med, 1999, 340: 115-126.
18. Glass C K, Witztum J L. Atherosclerosis: The road ahead. Cell, 2001, 104: 503-516.
19. Ridker P M, Cannon C P, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med, 2005, 352: 20-28.
20. Reynolds G D, Vance R P. C-reactive protein immunohistochemical localization in normal and atherosclerotic human aortas. Arch Pathol Lab Med, 1987, 111: 265-269.
21. Zhang Y X, Cliff W J, Schoefl G I, et al. Coronary C-reactive protein distribution: Its relation to development of atherosclerosis. Atherosclerosis, 1999, 145: 375-379.
22. Chang M K, Binder C J, Torzewski M, et al. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci USA, 2002, 99: 13043-13048.
23. Bhakdi S, Torzewski M, Paprotka K, et al. Possible protective role for C-reactive protein in atherogenesis: Complement activation by modified lipoproteins halts before detrimental terminal sequence. Circulation, 2004, 109: 1870-1876.
24. Torzewski J, Torzewski M, Bowyer D E, et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol, 1998, 18: 1386-1392.
25. Devaraj S, Singh U, Jialal I. The evolving role of C-reactive protein in atherothrombosis. Clin Chem, 2009, 55: 229-238.
26. Paul A, Yeh E T, Chan L. A proatherogenic role for C-reactive protein in vivo. Curr Opin Lipidol, 2005, 16: 512-517.
27. Pepys M B, Hirschfield G M, Tennent G A, et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature, 2006, 440: 1217-1221.
28. Korngold E C, Januzzi J L Jr, Gantzer M L, et al. Amino-terminal pro-B-type natriuretic peptide and high-sensitivity C-reactive protein as predictors of sudden cardiac death among women. Circulation, 2009, 119: 2868-2876.
29. Khera A, de Lemos J A, Peshock R M, et al. Relationship between C-reactive protein and subclinical atherosclerosis: The Dallas Heart Study. Circulation, 2006, 113: 38-43.
30. Bos M J, Schipper C M, Koudstaal P J, et al. High serum C-reactive protein level is not an independent predictor for stroke: The Rotterdam Study. Circulation, 2006, 114: 1591-1598.
31. Paul A, Ko K W, Li L, et al. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation, 2004, 109: 647-655.
32. Hirschfield G M, Gallimore J R, Kahan M C, et al. Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA, 2005, 102: 8309-8314.
33. Kovacs A, Tornvall P, Nilsson R, et al. Human C-reactive protein slows atherosclerosis development in a mouse model with human-like hypercholesterolemia. Proc Natl Acad Sci USA, 2007, 104: 13768-13773.
34. Teupser D, Weber O, Rao T N, et al. No reduction of atherosclerosis in C-reactive protein (CRP)-deficient mice. J Biol Chem, 2011, 286: 6272-6279.
35. Koike T, Kitajima S, Yu Y, et al. Human C-reactive protein does not promote atherosclerosis in transgenic rabbits. Circulation, 2009, 120: 2088-2094.
36. Verma S, Li S H, Badiwala M V, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation, 2002, 105: 1890-1896.
37. Verma S, Wang C H, Li S H, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation, 2002, 106: 913-919.
38. Clapp B R, Hirschfield G M, Storry C, et al. Inflammation and endothelial function: direct vascular effects of human C-reactive protein on nitric oxide bioavailability. Circulation, 2005, 111: 1530-1536.
39. Taylor K E, Giddings J C, van Den Berg C W. C-reactive protein-induced in vitro endothelial cell activation is an artefact caused by azide and lipopolysaccharide. Arterioscler Thromb Vasc Biol, 2005, 25: 1225-1230.
40. Schwartz R, Osborne-Lawrence S, Hahner L, et al. C-reactive protein downregulates endothelial NO synthase and attenuates reendothelialization in vivo in mice. Circ Res, 2007, 100: 1452-1459.
41. Devaraj S, Du Clos T W, Jialal I. Binding and internalization of C-reactive protein by Fcgamma receptors on human aortic endothelial cells mediates biological effects. Arterioscler Thromb Vasc Biol, 2005, 25: 1359-1363.
42. Pepys M B, Gallimore J R, Lloyd J, et al. Isolation and characterization of pharmaceutical grade human pentraxins, serum amyloid P component and C-reactive protein, for clinical use. J Immunol Methods, 2012, 384: 92-102.
43. Singh U, Devaraj S, Dasu M R, et al. C-reactive protein decreases interleukin-10 secretion in activated human monocyte-derived macrophages via inhibition of cyclic AMP production. Arterioscler Thromb Vasc Biol, 2006, 26: 2469-2475.
44. + monocyte-derived dendritic cell differentiation, maturation and function. Eur J Immunol, 2006, 36: 2993-3006.
45. van Vre E A, Bult H, Hoymans V Y, et al. Human C-reactive protein activates monocyte-derived dendritic cells and induces dendritic cell-mediated T-cell activation. Arterioscler Thromb Vasc Biol, 2008, 28: 511-518.
46. Pepys M B, Hawkins P N, Kahan M C, et al. Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. Circ Res, 2005, 97: e97-103.
47. Liu C, Wang S, Deb A, et al. Proapoptotic, antimigratory, antiproliferative, and antiangiogenic effects of commercial C-reactive protein on various human endothelial cell types in vitro: Implications of contaminating presence of sodium azide in commercial preparation. Circ Res, 2005, 97: 135-143.
48. Zhao J, Ji S R, Wu Y. C-reactive protein - A link between cardiovascular disease and inflammation. Acta Biophys Sin, 2010, 26: 87-96.
49. Schwedler S B, Filep J G, Galle J, et al. C-reactive protein: A family of proteins to regulate cardiovascular function. Am J Kidney Dis, 2006, 47: 212-222.
50. Singh S K, Suresh M V, Voleti B, et al. The connection between C-reactive protein and atherosclerosis. Ann Med, 2008, 40: 110-120.
51. Eisenhardt S U, Thiele J R, Bannasch H, et al. C-reactive protein: How conformational changes influence inflammatory properties. Cell Cycle, 2009, 8: 3885-3892.
52. Slevin M, Krupinski J. A role for monomeric C-reactive protein in regulation of angiogenesis, endothelial cell inflammation and thrombus formation in cardiovascular/cerebrovascular disease? Histol Histopathol, 2009, 24: 1473-1478.
53. Filep J G. Platelets affect the structure and function of C-reactive protein. Circ Res, 2009, 105: 109-111.
54. Potempa L A, Maldonado B A, Laurent P, et al. Antigenic, electrophoretic and binding alterations of human C-reactive protein modified selectively in the absence of calcium. Mol Immunol, 1983, 20: 1165-1175.
55. Wang M Y, Ji S R, Bai C J, et al. A redox switch in C-reactive protein modulates activation of endothelial cells. FASEB J, 2011, 25: 3186-3196.
56. Khreiss T, Jozsef L, Hossain S, et al. Loss of pentameric symmetry of C-reactive protein is associated with delayed apoptosis of human neutrophils. J Biol Chem, 2002, 277: 40775-40781.
57. Kresl J J, Potempa L A, Anderson B E. Conversion of native oligomeric to a modified monomeric form of human C-reactive protein. Int J Biochem Cell Biol, 1998, 30: 1415-1426.
58. Motie M, Brockmeier S, Potempa L A. Binding of model soluble immune complexes to modified C-reactive protein. J Immunol, 1996, 156: 4435-4441.
59. Ji S R, Wu Y, Potempa L A, et al. Interactions of C-reactive protein with low-density lipoproteins: Implications for an active role of modified C-reactive protein in atherosclerosis. Int J Biochem Cell Biol, 2006, 38: 648-661.
60. Ji S R, Wu Y, Potempa L A, et al. Effect of modified C-reactive protein on complement activation: A possible complement regulatory role of modified or monomeric C-reactive protein in atherosclerotic lesions. Arterioscler Thromb Vasc Biol, 2006, 26: 935-941.
61. Singh S K, Suresh M V, Hammond D J Jr, et al. Binding of the monomeric form of C-reactive protein to enzymatically-modified low-density lipoprotein: Effects of phosphoethanolamine. Clin Chim Acta, 2009, 406: 151-155.
62. Biro A, Rovo Z, Papp D, et al. Studies on the interactions between C-reactive protein and complement proteins. Immunology, 2007, 121: 40-50.
63. Sjowal, C, Wettero J, Bengtsson T, et al. Solid-phase classical complement activation by C-reactive protein (CRP) is inhibited by fluidphase CRP-C1q interaction. Biochem Biophys Res Commun, 2007, 352: 251-258.
64. Mihlan M, Stippa S, Jozsi M, et al. Monomeric CRP contributes to complement control in fluid phase and on cellular surfaces and increases phagocytosis by recruiting factor H. Cell Death Differ, 2009, 16: 1630-1640.
65. Lauer N, Mihlan M, Hartmann A, et al. Complement regulation at necrotic cell lesions is impaired by the age-related macular degeneration-associated factor-H His402 risk variant. J Immunol, 2011, 187: 4374-4383.
66. Mihlan M, Blom A M, Kupreishvili K, et al. Monomeric C-reactive protein modulates classic complement activation on necrotic cells. FASEB J, 2011, 25: 4198-4210.
67. Yang X W, Tan Y, Yu F, et al. Interference of antimodified C-reactive protein autoantibodies from lupus nephritis in the biofunctions of modified C-reactive protein. Hum Immunol, 2012, 73: 156-163.
68. Rzychon M, Zegers I, Schimmel H. Analysis of the physicochemical state of C-reactive protein in different preparations including 2 certified reference materials. Clin Chem, 2010, 56: 1475-1482.
69. Wu Y, Ji S R, Wang H W, et al. Study of the spontaneous dissociation of rabbit C-reactive protein. Biochemistry (Mosc), 2002, 67: 1377-1382.
70. Potempa L A, Siegel J N, Fiedel B A, et al. Expression, detection and assay of a neoantigen (Neo-CRP) associated with a free, human C-reactive protein subunit. Mol Immunol, 1987, 24: 531-541.
71. Hakobyan S, Harris C L, van Den Berg C W, et al. Complement factor H binds to denatured rather than to native pentameric C-reactive protein. J Biol Chem, 2008, 283: 30451-30460.
72. Wang H W, Sui S F. Dissociation and subunit rearrangement of membrane-bound human C-reactive proteins. Biochem Biophys Res Commun, 2001, 288: 75-79.
73. Ji S R, Wu Y, Zhu L, et al. Cell membranes and liposomes dissociate C-reactive protein (CRP) to form a new, biologically active structural intermediate: mCRP(m). FASEB J, 2007, 21: 284-294.
74. Thompson D, Pepys M B, Wood S P. The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure, 1999, 7: 169-177.
75. Gershov D, Kim S, Brot N, et al. C-Reactive protein binds to apop-totic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: Implications for systemic autoimmunity. J Exp Med, 2000, 192: 1353-1364.
76. Eisenhardt S U, Habersberger J, Murphy A, et al. Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques. Circ Res, 2009, 105: 128-137.
77. Schwedler S B, Guderian F, Dammrich J, et al. Tubular staining of modified C-reactive protein in diabetic chronic kidney disease. Nephrol Dial Transplant, 2003, 18: 2300-2307.
78. Slevin M, Matou-Nasri S, Turu M, et al. Modified C-reactive protein is expressed by stroke neovessels and is a potent activator of angiogenesis in vitro. Brain Pathol, 2010, 20: 151-165.
79. Molins B, Pena E, De La Torre R, et al. Monomeric C-reactive protein is prothrombotic and dissociates from circulating pentameric C-reactive protein on adhered activated platelets under flow. Cardiovasc Res, 2011, 92: 328-337.
80. Strang F, Scheichl A, Chen Y C, et al. Amyloid plaques dissociate pentameric to monomeric C-reactive protein: A novel pathomechanism driving cortical inflammation in Alzheimer's disease? Brain Pathol, 2012, 22: 337-346.
81. Habersberger J, Strang F, Scheichl A, et al. Circulating microparticles generate and transport monomeric C-reactive protein in patients with myocardial infarction. Cardiovasc Res, 2012, 96: 64-72.
82. Wang M S, Messersmith R E, Reed S M. Membrane curvature recognition by C-reactive protein using lipoprotein mimics. Soft Matter, 2012, 8: 3909-3918.
83. Hammond D J Jr, Singh S K, Thompson J A, et al. Identification of acidic pH-dependent ligands of pentameric C-reactive protein. J Biol Chem, 2010, 285: 36235-36244.
84. Ciubotaru I, Potempa L A, Wander R C. Production of modified C-reactive protein in U937-derived macrophages. Exp Biol Med (Maywood), 2005, 230: 762-770.
85. Wang M S, Black J C, Knowles M K, et al. C-reactive protein (CRP) aptamer binds to monomeric but not pentameric form of CRP. Anal Bioanal Chem, 2011, 401: 1309-1318.
86. Tan Y, Yu F, Qu Z, et al. Modified C-reactive protein might be a target autoantigen of TINU syndrome. Clin J Am Soc Nephrol, 2011, 6: 93-100.
87. Wettero J, Nilsson L, Jonasson L, et al. Reduced serum levels of autoantibodies against monomeric C-reactive protein (CRP) in patients with acute coronary syndrome. Clin Chim Acta, 2009, 400: 128-131.
88. Sjowall C, Bengtsson A A, Sturfelt G, et al. Serum levels of autoantibodies against monomeric C-reactive protein are correlated with disease activity in systemic lupus erythematosus. Arthritis Res Ther, 2004, 6: R87-R94.
89. Wettero J, Nilsson L, Jonasson L, et al. Reduced serum levels of autoantibodies against monomeric C-reactive protein (CRP) in patients with acute coronary syndrome. Clin Chim Acta, 2009, 400: 128-131.
90. Hoshino Y, Shioji K, Nakamura H, et al. From oxygen sensing to heart failure: Role of thioredoxin. Antioxid Redox Signal, 2007, 9: 689-699.
91. Yamawaki H, Haendeler J, Berk B C. Thioredoxin: A key regulator of cardiovascular homeostasis. Circ Res, 2003, 93: 1029-1033.
92. Ji S R, Ma L, Bai C J, et al. Monomeric C-reactive protein activates endothelial cells via interaction with lipid raft microdomains. FASEB J, 2009, 23: 1806-1816.
93. Simons K, Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol, 2000, 1: 31-41.
94. Li R, Ren M, Luo M, et al. Monomeric C-reactive protein alters fibrin clot properties on endothelial cells. Thromb Res, 2012, 129: e251-256.
95. Vilahur G, Hernandez-Vera R, Molins B, et al. Short-term myocardial ischemia induces cardiac modified C-reactive protein expression and proinflammatory gene (cyclo-oxygenase-2, monocyte chemoattractant protein-1, and tissue factor) upregulation in peripheral blood mononuclear cells. J Thromb Haemost, 2009, 7: 485-493.
96. Patel D N, King C A, Bailey S R, et al. Interleukin-17 stimulates C-reactive protein expression in hepatocytes and smooth muscle cells via p38 MAPK and ERK1/2-dependent NF-kappaB and C/EBPbeta activation. J Biol Chem, 2007, 282: 27229-27238.
97. Venugopal S K, Devaraj S, Jialal I. Macrophage conditioned medium induces the expression of C-reactive protein in human aortic endothelial cells: Potential for paracrine/autocrine effects. Am J Pathol, 2005, 166: 1265-1271.
98. Jabs W J, Theissing E, Nitschke M, et al. Local generation of C-reactive protein in diseased coronary artery venous bypass grafts and normal vascular tissue. Circulation, 2003, 108: 1428-1431.
99. Yasojima K, Schwab C, McGeer E G, et al. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol, 2001, 158: 1039-1051.
100. Nishihira K, Yamashita A, Imamura T, et al. Thioredoxin in coronary culprit lesions: Possible relationship to oxidative stress and intraplaque hemorrhage. Atherosclerosis, 2008, 201: 360-367.
101. Burke-Gaffney A, Callister M E, Nakamura H. Thioredoxin: Friend or foe in human disease? Trends Pharmacol Sci, 2005, 26: 398-404.
102. Watanabe R, Nakamura H, Masutani H, et al. Anti-oxidative, anti-cancer and anti-inflammatory actions by thioredoxin 1 and thioredoxin-binding protein-2. Pharmacol Ther, 2010, 127: 261-270.
103. El Kebir D, Zhang Y, Potempa L A, et al. C-reactive protein-derived peptide 201-206 inhibits neutrophil adhesion to endothelial cells and platelets through CD32. J Leukoc Biol, 2011, 90: 1167-1175.
104. Schwedler S B, Hansen-Hagge T, Reichert M, et al. Monomeric C-reactive protein decreases acetylated LDL uptake in human endothelial cells. Clin Chem, 2009, 55: 1728-1731.
105. Schwedler S B, Amann K, Wernicke K, et al. Native C-reactive protein (CRP) increases, whereas modified CRP reduces atherosclerosis in ApoE-knockout-mice. Circulation, 2005, 112: 1016-1023.
106. Kemp M, Go Y M, Jones D P. Nonequilibrium thermodynamics of thiol/disulfide redox systems: A perspective on redox systems biology. Free Radic Biol Med, 2008, 44: 921-937.